208 related articles for article (PubMed ID: 32913121)
1. Ascorbic acid enhances low-density lipoprotein receptor expression by suppressing proprotein convertase subtilisin/kexin 9 expression.
Wang D; Yang X; Chen Y; Gong K; Yu M; Gao Y; Wu X; Hu H; Liao C; Han J; Duan Y
J Biol Chem; 2020 Nov; 295(47):15870-15882. PubMed ID: 32913121
[TBL] [Abstract][Full Text] [Related]
2. Schisandrin A in
Kim HJ; Park SK; Park SH; Lee YG; Park JH; Hwang JT; Chung MY
J Microbiol Biotechnol; 2024 Feb; 34(2):425-435. PubMed ID: 37997262
[No Abstract] [Full Text] [Related]
3. Polydatin ameliorates low-density lipoprotein cholesterol and lipid metabolism by downregulating proprotein convertase subtilisin/kexin type 9 (PCSK9) in triple-negative breast cancer with hyperlipidemia.
Liu M; Zhang Q
Am J Cancer Res; 2024; 14(1):52-72. PubMed ID: 38323270
[TBL] [Abstract][Full Text] [Related]
4. Gallic Acid Can Promote Low-Density Lipoprotein Uptake in HepG2 Cells via Increasing Low-Density Lipoprotein Receptor Accumulation.
Zhang D; Zhou Q; Yang X; Zhang Z; Wang D; Hu D; Huang Y; Sheng J; Wang X
Molecules; 2024 Apr; 29(9):. PubMed ID: 38731489
[TBL] [Abstract][Full Text] [Related]
5. Pseurotin A Validation as a Metastatic Castration-Resistant Prostate Cancer Recurrence-Suppressing Lead via PCSK9-LDLR Axis Modulation.
Abdelwahed KS; Siddique AB; Ebrahim HY; Qusa MH; Mudhish EA; Rad AH; Zerfaoui M; Abd Elmageed ZY; El Sayed KA
Mar Drugs; 2023 Mar; 21(4):. PubMed ID: 37103355
[TBL] [Abstract][Full Text] [Related]
6. A novel small-molecule PCSK9 inhibitor E28362 ameliorates hyperlipidemia and atherosclerosis.
Wang WZ; Liu C; Luo JQ; Lei LJ; Chen MH; Zhang YY; Sheng R; Li YN; Wang L; Jiang XH; Xiao TM; Zhang YH; Li SW; Wu YX; Xu Y; Xu YN; Si SY
Acta Pharmacol Sin; 2024 May; ():. PubMed ID: 38811775
[TBL] [Abstract][Full Text] [Related]
7. Pseudorabies virus upregulates low-density lipoprotein receptors to facilitate viral entry.
Ma Y-X; Chai Y-J; Han Y-Q; Zhao S-B; Yang G-Y; Wang J; Ming S-L; Chu B-B
J Virol; 2024 Jan; 98(1):e0166423. PubMed ID: 38054618
[TBL] [Abstract][Full Text] [Related]
8. Discovery of (2-(4-Substituted phenyl)quinolin-4-yl)(4-isopropylpiperazin-1-yl)methanone Derivatives as Potent Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors.
Wang X; Zhang L; Wang X; Zhu D; Xu G; Li H; Zhang L
ChemMedChem; 2024 Jan; 19(2):e202300498. PubMed ID: 38054966
[TBL] [Abstract][Full Text] [Related]
9. Downregulation of low-density lipoprotein receptor mRNA in lymphatic endothelial cells impairs lymphatic function through changes in intracellular lipids.
Vachon L; Smaani A; Tessier N; Jean G; Demers A; Milasan A; Ardo N; Jarry S; Villeneuve L; Alikashani A; Finherty V; Ruiz M; Sorci-Thomas MG; Mayer G; Martel C
Theranostics; 2022; 12(3):1440-1458. PubMed ID: 35154499
[No Abstract] [Full Text] [Related]
10. PCSK9 stimulates Syk, PKCδ, and NF-κB, leading to atherosclerosis progression independently of LDL receptor.
Shin D; Kim S; Lee H; Lee HC; Lee J; Park HW; Fukai M; Choi E; Choi S; Koo BJ; Yu JH; No G; Cho S; Kim CW; Han D; Jang HD; Kim HS
Nat Commun; 2024 Mar; 15(1):2789. PubMed ID: 38555386
[TBL] [Abstract][Full Text] [Related]
11. In Silico Insights into Protein-protein Interaction Disruptive Mutations in the PCSK9-LDLR complex.
Martin WR; Lightstone FC; Cheng F
Int J Mol Sci; 2020 Feb; 21(5):. PubMed ID: 32106405
[TBL] [Abstract][Full Text] [Related]
12. Potential use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition and prevention method in viral infection.
Muzammil K; Hooshiar MH; Varmazyar S; Omar TM; Karim MM; Aadi S; Kalavi S; Yasamineh S
Microb Cell Fact; 2024 Mar; 23(1):90. PubMed ID: 38528584
[TBL] [Abstract][Full Text] [Related]
13. PCSK9 deficiency reduces atherosclerosis, apolipoprotein B secretion, and endothelial dysfunction.
Sun H; Krauss RM; Chang JT; Teng BB
J Lipid Res; 2018 Feb; 59(2):207-223. PubMed ID: 29180444
[TBL] [Abstract][Full Text] [Related]
14. Targeting PCSK9 to upregulate MHC-II on the surface of tumor cells in tumor immunotherapy.
Wang H; Zhang X; Zhang Y; Shi T; Zhang Y; Song X; Liu B; Wang Y; Wei J
BMC Cancer; 2024 Apr; 24(1):445. PubMed ID: 38600469
[TBL] [Abstract][Full Text] [Related]
15. Synthesis of Moracin C and Its Derivatives with a 2-arylbenzofuran Motif and Evaluation of Their PCSK9 Inhibitory Effects in HepG2 Cells.
Masagalli JN; BasavanaGowda MK; Chae HS; Choi WJ
Molecules; 2021 Mar; 26(5):. PubMed ID: 33801308
[TBL] [Abstract][Full Text] [Related]
16. Leveraging Bidirectional Nature of Allostery To Inhibit Protein-Protein Interactions (PPIs): A Case Study of PCSK9-LDLR Interaction.
Sinha K; Basu I; Shah Z; Shah S; Chakrabarty S
J Chem Inf Model; 2024 May; 64(9):3923-3932. PubMed ID: 38615325
[TBL] [Abstract][Full Text] [Related]
17. PCSK9 regulates neuronal apoptosis by adjusting ApoER2 levels and signaling.
Kysenius K; Muggalla P; Mätlik K; Arumäe U; Huttunen HJ
Cell Mol Life Sci; 2012 Jun; 69(11):1903-16. PubMed ID: 22481440
[TBL] [Abstract][Full Text] [Related]
18. Targeting PCSK9 as a key player in lipid metabolism: exploiting the therapeutic and biosensing potential of aptamers.
Mahjoubin-Tehran M; Rezaei S; Santos RD; Jamialahmadi T; Almahmeed W; Sahebkar A
Lipids Health Dis; 2024 May; 23(1):156. PubMed ID: 38796450
[TBL] [Abstract][Full Text] [Related]
19. Dyslipidemia in rat fed with high-fat diet is not associated with PCSK9-LDL-receptor pathway but ageing.
Jia YJ; Liu J; Guo YL; Xu RX; Sun J; Li JJ
J Geriatr Cardiol; 2013 Dec; 10(4):361-8. PubMed ID: 24454330
[TBL] [Abstract][Full Text] [Related]
20. Research progress in the correlation between SREBP/PCSK9 pathway and lipid metabolism disorders induced by antipsychotics.
Ma J; Zheng Y; Sun F; Fan Y; Fan Y; Su X; Wang Z; Weng N; Li R
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 Oct; 48(10):1529-1538. PubMed ID: 38432882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
